Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2024 08:45 ET | Source: GRI Bio, Inc.

GRI Bio to Present at the 2024 European Respiratory Congress

LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
August 14, 2024 08:05 ET | Source: GRI Bio, Inc.

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
July 15, 2024 09:05 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
July 11, 2024 09:20 ET | Source: GRI Bio, Inc.

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
July 08, 2024 09:05 ET | Source: GRI Bio, Inc.

GRI Bio Regains Compliance with Nasdaq

LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
July 02, 2024 09:05 ET | Source: GRI Bio, Inc.

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice ...
July 01, 2024 08:45 ET | Source: GRI Bio, Inc.

GRI Bio to Present at the 8th Annual IPF Summit

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
June 28, 2024 16:05 ET | Source: GRI Bio, Inc.

GRI Bio Announces Closing of $4.0 Million Public Offering

LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
June 27, 2024 09:00 ET | Source: GRI Bio, Inc.

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation LA JOLLA, CA, June 27, 2024 ...
June 27, 2024 08:00 ET | Source: GRI Bio, Inc.

GRI Bio Announces Pricing of $4 Million Public Offering

LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...